Phase II Trial Finds LuPSMA May be Effective for Men with mCRPC

The results, presented at the 2020 ASCO Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer who were previously treated with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news